UBS Group
TLX

UBS Group’s Telix Pharmaceuticals TLX Stock Holding History

UBS Group’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55M Buy
134,698
+102,398
+317% +$1.04M ﹤0.01% 5338
2026
Q1 		$309K Buy
32,300
+30,336
+1,545% +$231K ﹤0.01% 6382
2025
Q4 		$14.7K Sell
1,964
-3,601
-65% -$34.7K ﹤0.01% 7984
2025
Q3 		$53.3K Sell
5,565
-556
-9% -$6.81K ﹤0.01% 7516
2025
Q2 		$98.4K Buy
6,121
+2,470
+68% +$41.5K ﹤0.01% 7254
2025
Q1 		$61.2K Sell
3,651
-79
-2% -$1.38K ﹤0.01% 7429
2024
Q4 		$57.4K Buy
+3,730
New +$58.6K ﹤0.01% 7215

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return

UBS Group's TLX Position: Q2 2026 in Review

UBS Group increased its Telix Pharmaceuticals (TLX) stake by 317% in Q2 2026, buying an estimated $1.04M and bringing the position to 134,698 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #5338.

UBS Group first reported a position in TLX in Q4 2024 and has held it in 7 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • UBS Group held 134,698 shares of Telix Pharmaceuticals worth $1.55M as of Q2 2026.
  • UBS Group bought 102,398 Telix Pharmaceuticals shares in Q2 2026, an estimated $1.04M.
  • Telix Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5338 holding.
  • UBS Group first reported a position in Telix Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.